Clinical trials: Nervous System Complication
Fabry Disease
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry…
- Trial name
- NCT03566017
- Testing
- pegunigalsidase alfa
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 97 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Diabetic Neuropathies
Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
- Trial name
- NCT00229437
- Testing
- TAK-128
- Where
- 48 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- Takeda
Diabetic Neuropathy, Painful
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to assess the safety and efficacy of the long-term use of pregabalin at doses up to 600 mg/day in patients with painful diabetic peripheral neuropathy who have completed 13 weeks of dosing in Study…
- Trial name
- NCT00553280
- Testing
- pregabalin
- Where
- 27 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathies
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.
- Trial name
- NCT00760955
- Testing
- TAK-583
- Where
- 38 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Takeda
Diabetes Mellitus, Diabetic Neuropathy, Painful
Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy
EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor.
- Trial name
- NCT00073034
- Testing
- EAA-090
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Peripheral Neuropathy, Painful Diabetic Neuropathy
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in…
- Conditions
- Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Neuropathies, Painful
- Trial name
- NCT04005287
- Testing
- WST-057 (4% pirenzepine) Lose Dose 2mL, WST-057 (4% pirenzepine) High Dose 4mL
- Where
- 5 sites in Canada
- Volunteers
- 58 people
- Sponsor
- WinSanTor, Inc
Short Stature, Idiopathic, Infant, Small for Gestational Age
Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
- Conditions
- Short Stature, Idiopathic, Infant, Small for Gestational Age, Growth Hormone Deficiency, Chronic Renal Failure
- Trial name
- NCT03015909
- Testing
- Somatropin
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- LG Life Sciences
Neuropathic Pain, Phantom Limb Pain
Clinical Evaluation of the Medical Device (MD) (Caloprothese Connected Kit, CCK)
Neuropathic pain is common in limb amputees and causes reductions in activity and participation as well as impaired quality of life.
- Trial name
- KCC (NCT04748484)
- Testing
- KCC Active or inactive
- Where
- 4 sites in France
- Volunteers
- 12 people
- Sponsor
- Gregand Innovations
Cerebral Hemorrhage, Head Injury
Biomarkers Correlation With Volemia
The purpose of this study is to determine whether the Biomarkers (pro adrenomedullin (MR proADM), pro arginin vasopressin (CT proAVP), pro atrial natriuretic peptid (MR proANP), Pro Endothelin) changes at Day 2, Day 5 and Day 7…
- Conditions
- Cerebral Hemorrhage, Head Injury, Non Traumatic Post Surgery, Poly Trauma Patients Without Heart Failure
- Trial name
- ENVOL (NCT01858675)
- Testing
- Biomarkers, red blood cells and plasma assessment
- Where
- France
- Volunteers
- 66 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Insomnia, Renal Impairment
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
Objective： 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2.
- Trial name
- NCT06671444
- Testing
- YZJ-1139
- Where
- 3 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Advanced Solid Malignancy, Safety and Tolerability
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future.
- Conditions
- Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT01226316
- Testing
- AZD5363
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 285 people
- Sponsor
- AstraZeneca
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Spinal Cord Injury
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of pain associated with spinal cord injury.
- Trial name
- NCT01135108
- Testing
- KAI-1678
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- KAI Pharmaceuticals
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Neurological Complication, in Particular TNS or CES
Observational Study on 2-chloroprocaine Hydrochloride 1%
The present study aims to evaluate the relationship between spinal block with 1% solution of 2-chloroprocaine hydrochloride and the onset of all possible neurological adverse events, with particular attention to Transient…
- Trial name
- PASS (NCT02067806)
- Testing
- 2-chloroprocaine hydrochloride, 1%
- Where
- Belgium
- Volunteers
- 394 people
- Sponsor
- Sintetica SA
Diabetic Neuropathy, Painful
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
- Trial name
- NCT00156078
- Testing
- pregabalin
- Where
- 35 sites in Argentina, Brazil and 17 more
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.
- Trial name
- NCT06495424
- Testing
- Capsaicin 8%
- Where
- 10 sites in United States
- Volunteers
- 144 people
- Sponsor
- Averitas Pharma, Inc.
Hypertension, Cardiac Arrhythmias
Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction
Arterial hypertension causes adverse effects on the entire cardiovascular system, with effects centrally such as diastolic dysfunction and structural changes of the left ventricle and, peripherally such as endothelial dysfunction…
- Conditions
- Hypertension, Cardiac Arrhythmias, Diabetes Mellitus, Renal Insufficiency
- Trial name
- NCT02148991
- Where
- 2 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Painful Diabetic Neuropathy
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
The purpose of this post-market study is to evaluate changes in pain and neurological function with high frequency, 10 kHz spinal cord stimulation (SCS) therapy in patients with chronic, intractable lower limb pain associated…
- Trial name
- PDN-SENSORY (NCT05777317)
- Testing
- 10 kHz SCS, CMM alone
- Where
- 2 sites in United States
- Volunteers
- 143 people
- Sponsor
- Nevro Corp